Get started
Author

Amir Snapir

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
2019 · Karim Fizazi, Neal Shore, et al. · New England Journal of Medicine · 947
PDF
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
2020 · Karim Fizazi, Neal Shore, et al. · New England Journal of Medicine · 376
PDF
Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep
2007 · E. HUUPPONEN, A. MAKSIMOW, et al. · Acta Anaesthesiologica Scandinavica · 334
Effects of Low and High Plasma Concentrations of Dexmedetomidine on Myocardial Perfusion and Cardiac Function in Healthy Male Subjects
2006 · Amir Snapir, Jussi Posti, et al. · Anesthesiology · 131
PDF
An insertion/deletion polymorphism in the α2b-adrenergic receptor gene is a novel genetic risk factor for acute coronary events
2001 · Amir Snapir, Paula Heinonen, et al. · Journal of the American College of Cardiology · 107
Variation in the alpha2B-adrenoceptorgene as a risk factor for prehospitalfatal myocardial infarction and sudden cardiac death
2003 · Amir Snapir, Jussi Mikkelsson, et al. · Journal of the American College of Cardiology · 103
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
2020 · Malaka Ameratunga, Irene Braña, et al. · British Journal of Cancer · 95
PDF
Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception
2015 · Michael Hughes, Amir Snapir, et al. · Rheumatology · 74
Effects of common polymorphisms in the α1A-, α2B-, β1- and β2-adrenoreceptors on haemodynamic responses to adrenaline
2003 · Amir SNAPIR, Juha KOSKENVUO, et al. · Clinical Science · 72
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
2015 · Christophe Massard, Heidi M. Penttinen, et al. · European Urology · 65
Assessing the depth of dexmedetomidine‐induced sedation with electroencephalogram (EEG)‐based spectral entropy
2006 · A. Maksimow, A. Snapir, et al. · Acta Anaesthesiologica Scandinavica · 55
G-protein β3 subunit C825T polymorphism: no association with risk for hypertension and obesity
2001 · Amir Snapir, Paula Heinonen, et al. · Journal of Hypertension · 50
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
2020 · Karim Fizazi, Neal D. Shore, et al. · Journal of Clinical Oncology · 49
Prospective–Retrospective Biomarker Analysis for Regulatory Consideration: white Paper from the Industry Pharmacogenomics Working Group
2011 · Scott D Patterson, Nadine Cohen, et al. · Pharmacogenomics · 47
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
2021 · Matthew R. Smith, Neal Shore, et al. · European Journal of Cancer · 36
PDF
A double-blind, randomized, placebo-controlled crossover trial of the 2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis
2014 · A. L. Herrick, A. K. Murray, et al. · Rheumatology · 36
Effects of nitric oxide synthase inhibition on dexmedetomidine-induced vasoconstriction in healthy human volunteers
2008 · A. Snapir, P. Talke, et al. · British Journal of Anaesthesia · 35
Challenges in Obtaining Adequate Genetic Sample Sets in Clinical Trials: The Perspective of the Industry Pharmacogenomics Working Group
2011 · A W Warner, A Bhathena, et al. · Clinical Pharmacology & Therapeutics · 29
Effect of α2B-Adrenoceptor Polymorphism on Peripheral Vasoconstriction in Healthy Volunteers
2005 · Pekka Talke, Claudia Stapelfeldt, et al. · Anesthesiology · 29
PDF
Determinants of coronary flow velocity reserve in healthy young men
2006 · Tuomas O. Kiviniemi, Amir Snapir, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 24
Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group
2008 · C M Bromley, S Close, et al. · The Pharmacogenomics Journal · 22
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
2019 · Karim Fizazi, Neal D. Shore, et al. · Journal of Clinical Oncology · 21
Estimation of cardiac output in a pharmacological trial using a simple method based on arterial blood pressure signal waveform: a comparison with pulmonary thermodilution and echocardiographic methods
2006 · Jani Penttilä, Amir Snapir, et al. · European Journal of Clinical Pharmacology · 20
Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction
2005 · Pekka Talke, Claudia Stapelfeldt, et al. · Pharmacogenetics and Genomics · 19
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
2020 · Hiroji Uemura, Hisashi Matsushima, et al. · International Journal of Clinical Oncology · 18
PDF
Works count: 58
Citation count: 2,949
H-index: 21
I10-index: 32
Year
Topic
Type